Integration of phage and yeast display platforms: A reliable and cost effective approach for binning of peptides as displayed on-phage.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2020
Historique:
received: 02 10 2019
accepted: 16 05 2020
entrez: 2 6 2020
pubmed: 2 6 2020
medline: 21 8 2020
Statut: epublish

Résumé

Hundreds of target specific peptides are routinely discovered by peptide display platforms. However, due to the high cost of peptide synthesis only a limited number of peptides are chemically made for further analysis. Here we describe an accurate and cost effective method to bin peptides on-phage based on binding region(s), without any requirement for peptide or protein synthesis. This approach, which integrates phage and yeast display platforms, requires display of target and its alanine variants on yeast. Flow cytometry was used to detect binding of peptides on-phage to the target on yeast. Once hits were identified, they were synthesized to confirm their binding region(s) by HDX (Hydrogen deuterium exchange) and crystallography. Moreover, we have successfully shown that this approach can be implemented as part of a panning process to deplete non-functional peptides. This technique can be applied to any target that can be successfully displayed on yeast; it narrows down the number of peptides requiring synthesis; and its utilization during selection results in enrichment of peptide population against defined binding regions on the target.

Identifiants

pubmed: 32479512
doi: 10.1371/journal.pone.0233961
pii: PONE-D-19-27624
pmc: PMC7263589
doi:

Substances chimiques

IL12B protein, human 0
Interleukin-12 Subunit p40 0
Peptide Library 0
Recombinant Proteins 0
Alanine OF5P57N2ZX

Types de publication

Journal Article Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0233961

Déclaration de conflit d'intérêts

The authors [PP, ROS, JPT, SM, CT, JSC, KZ, JRF, QZ, FFZ, JW, JDD, JJC, AE, HB, YQ, SA] of this manuscript have no competing interest. Authors’ commercial affiliation with Eli Lilly does not alter their adherence to PLOS ONE policies on sharing data and materials on non-proprietary items.

Références

Nat Chem Biol. 2009 Jul;5(7):502-7
pubmed: 19483697
J Am Soc Mass Spectrom. 2012 Sep;23(9):1512-21
pubmed: 22692830
Proc Natl Acad Sci U S A. 2010 Apr 6;107(14):6252-7
pubmed: 20308586
J Mol Biol. 2008 Oct 17;382(4):931-41
pubmed: 18680750
Molecules. 2011 Jan 21;16(1):857-87
pubmed: 21258295
Immunity. 2018 Jan 16;48(1):45-58.e6
pubmed: 29287995
Biomed Res Int. 2018 May 24;2018:6232091
pubmed: 29992156
J Mol Biol. 2007 Jan 5;365(1):196-210
pubmed: 17059824
Nat Commun. 2014 Oct 30;5:5237
pubmed: 25354530
J Phys Chem B. 2017 Apr 20;121(15):3493-3501
pubmed: 27807976
ACS Med Chem Lett. 2018 Aug 01;9(9):912-916
pubmed: 30258540
Curr Drug Discov Technol. 2004 Jun;1(2):113-32
pubmed: 16472251
J Mol Biol. 2013 Jan 23;425(2):444-56
pubmed: 23159556
PLoS One. 2014 Oct 29;9(10):e111339
pubmed: 25353955
J Mol Biol. 2008 Oct 17;382(4):942-55
pubmed: 18708069
PLoS One. 2012;7(11):e49535
pubmed: 23166701
J Clin Invest. 2006 May;116(5):1218-22
pubmed: 16670765
Dermatol Ther (Heidelb). 2016 Mar;6(1):1-12
pubmed: 26714681
Methods Enzymol. 2000;328:333-63
pubmed: 11075354
Immunology. 2012 Feb;135(2):112-24
pubmed: 22044352
PLoS One. 2018 Jan 12;13(1):e0190850
pubmed: 29329326
J Mol Biol. 2004 Apr 23;338(2):299-310
pubmed: 15066433
Methods Mol Biol. 2015;1319:51-63
pubmed: 26060069
Nat Protoc. 2006;1(2):755-68
pubmed: 17406305
Infect Immun. 2005 Jan;73(1):444-52
pubmed: 15618183
J Mol Biol. 2015 Mar 27;427(6 Pt B):1513-1534
pubmed: 25284753
Sci Rep. 2016 May 17;6:26071
pubmed: 27184415
J Mol Biol. 2004 Sep 10;342(2):539-50
pubmed: 15327953
Curr Opin Chem Biol. 2017 Jun;38:24-29
pubmed: 28249193
Eur J Immunol. 2012 Sep;42(9):2263-73
pubmed: 22949325

Auteurs

Priyanka Pandya (P)

Department of Protein Engineering, Eli Lilly Biotechnology Center, San Diego, California, United States of America.

Robert O Sayers (RO)

Department of Protein Engineering, Eli Lilly Biotechnology Center, San Diego, California, United States of America.

Joey P Ting (JP)

Department of Protein Engineering, Eli Lilly Biotechnology Center, San Diego, California, United States of America.

Shaghayegh Morshedian (S)

Department of Protein Engineering, Eli Lilly Biotechnology Center, San Diego, California, United States of America.

Carina Torres (C)

Department of Protein Engineering, Eli Lilly Biotechnology Center, San Diego, California, United States of America.

Justine S Cudal (JS)

Department of Protein Engineering, Eli Lilly Biotechnology Center, San Diego, California, United States of America.

Kai Zhang (K)

Department of Protein Engineering, Eli Lilly Biotechnology Center, San Diego, California, United States of America.

Jonathan R Fitchett (JR)

Department of Protein Engineering, Eli Lilly Biotechnology Center, San Diego, California, United States of America.

Qing Zhang (Q)

Department of Protein Engineering, Eli Lilly Biotechnology Center, San Diego, California, United States of America.

Feiyu F Zhang (FF)

Lilly Research Laboratories, Discovery Chemistry Research and Technologies, San Diego, California, United States of America.

Jing Wang (J)

Lilly Research Laboratories, Discovery Chemistry Research and Technologies, San Diego, California, United States of America.

Jim D Durbin (JD)

Department of Structural Biology, Discovery Chemistry Research and Technologies, Eli Lilly and Company, Indianapolis, Indiana, United States of America.

Juan J Carrillo (JJ)

Department of Quantitative Biology, Discovery Chemistry Research and Technologies, Lilly Biotechnology Center, Eli Lilly and Company, Indianapolis, Indiana, United States of America.

Alfonso Espada (A)

Centro de Investigación Lilly, Alcobendas, Spain.

Howard Broughton (H)

Centro de Investigación Lilly, Alcobendas, Spain.

Yuewei Qian (Y)

Lilly Research Laboratories, Recombinant Protein Generation, Indianapolis, Indiana, United States of America.

Sepideh Afshar (S)

Department of Protein Engineering, Eli Lilly Biotechnology Center, San Diego, California, United States of America.

Articles similaires

T-Lymphocytes, Regulatory Lung Neoplasms Proto-Oncogene Proteins p21(ras) Animals Humans

Pathogenic mitochondrial DNA mutations inhibit melanoma metastasis.

Spencer D Shelton, Sara House, Luiza Martins Nascentes Melo et al.
1.00
DNA, Mitochondrial Humans Melanoma Mutation Neoplasm Metastasis

Prevalence and implications of fragile X premutation screening in Thailand.

Areerat Hnoonual, Sunita Kaewfai, Chanin Limwongse et al.
1.00
Humans Fragile X Mental Retardation Protein Thailand Male Female

Classifications MeSH